Treating HCV in PWID: Best Practices

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hepatitis C has become “curable” for >90% of those infected. But while universal HCV elimination is medically possible, this goal is compromised by certain populations who remain underscreened, undertreated, and underserved and continue to spread the virus. One such population is people who inject drugs (PWID).   

In this issue, Dr. Brianna Norton and Dr. Matthew Akiyama from the Albert Einstein College of Medicine analyze the most important data to explain how substance use impacts adherence and the risk of HCV reinfection.

Hosted on Acast. See acast.com/privacy for more information.